<DOC>
	<DOCNO>NCT01449565</DOCNO>
	<brief_summary>Extended-release naltrexone ( XR-NTX , VIVITROL ) FDA-approved medication efficacy treat alcohol dependence prevention relapse opioid dependence . It show promise reduce relapse amphetamine use among amphetamine-dependent , yet currently amphetamine-abstinent heterosexual . The investigator expand upon promising work determine whether monthly intramuscular injection naltrexone reduce methamphetamine ( meth ) use among actively use , meth-dependent men sex men ( MSM ) double-blind randomize controlled trial extended-release naltrexone versus placebo . The investigator focus MSM disproportionate intertwine epidemic meth use HIV population .</brief_summary>
	<brief_title>Extended-Release Naltrexone Treat Methamphetamine Dependence Men Who Have Sex With Men ( MSM )</brief_title>
	<detailed_description>The investigator enroll 100 sexually active , meth-dependent MSM randomize 1:1 receive monthly injection extended-release naltrexone ( n=50 ) placebo ( n=50 ) 12 week week 0 , 4 , 8 . Study participant see weekly site HIV Prevention Section San Francisco Department Public Health , provide urine drug test participate substance use counseling . All participant receive HIV risk-reduction counseling . Behavior assess use standardized measure via audio computer-assisted self-interview ( ACASI ) .</detailed_description>
	<mesh_term>Amphetamine-Related Disorders</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Inclusion criterion : 1. born male ; bear female identify female 2. report anal sex men prior six month influence meth ; 3. diagnose meth dependence determine SCID ; 4. interested stop reduce meth use ; 5. least one methpositive urine screen runin period ; 6. current acute illness require prolong medical care ; 7. chronic illness likely progress clinically trial participation ; 8. able willing provide inform consent adhere visit schedule ; 9. age 1865 year ; 10. baseline CBC , total protein , albumin , glucose , alkaline phosphatase , creatinine , BUN , total bilirubin , electrolytes without clinically significant abnormality determine investigator conjunction symptom , physical exam , medical history . Exclusion criterion : 1. psychiatric condition ( e.g . current depression suicidal ideation schizophrenia ) would preclude safe participation protocol ; 2. know intolerance and/or hypersensitivity naltrexone , carboxymethylcellulose , polylactidecopolymers ( PLG ) components diluent ; 3. current use dependence opioids ; know medical condition currently require likely require opioid analgesic ; positive opioid urine screening test 4. diagnosed current alcohol dependence determine SCID ; 5. current CD4 count &lt; 200 cells/mm3 ; 6. moderate severe liver disease ( AST and/or ALT &gt; 5 time upper limit normal ) ; 7. moderately severely impaired renal function ( eGFR &lt; 50 mL/min ) ; 8. thrombocytopenia coagulation disorder 9. currently participate another research study ; 10. pending legal proceeding high risk incarceration time plan study participation ; 11. condition , principal investigator 's judgment , interfere safe study participation adherence study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>methamphetamine</keyword>
	<keyword>high-risk sexual behavior</keyword>
	<keyword>HIV prevention</keyword>
</DOC>